NCT04209010 is a clinical trial of one-stage technique in Breast Cancer, sponsored by Aarhus University Hospital.

Who is sponsoring NCT04209010?

NCT04209010 is sponsored by Aarhus University Hospital.

What drugs are being tested in NCT04209010?

Interventions in NCT04209010: one-stage technique.

What condition does NCT04209010 study?

NCT04209010 studies Breast Cancer, Breast Carcinoma in Situ, Mammaplasty, Acellular Dermis.

Is NCT04209010 still recruiting?

NCT04209010 is currently completed. Last updated 3 January 2020.

Last reviewed 2020-01-03 · How we verify

NCT04209010

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immediate Breast Reconstruction With Acellular Dermal Matrix

Completed Last updated 3 January 2020

What this trial tests

trial testing one-stage technique in Breast Cancer in 44 participants. Completed in 17 March 2016.

Timeline

1 December 2012

Primary endpoint
17 March 2016

17 March 2016

Quick facts

Lead sponsor	Aarhus University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	44
Start date	1 December 2012
Primary completion	17 March 2016
Estimated completion	17 March 2016

Drugs / interventions tested

one-stage technique

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Breast Carcinoma in Situ — all drugs for Breast Carcinoma in Situ →
Mammaplasty — all drugs for Mammaplasty →
Acellular Dermis — all drugs for Acellular Dermis →

Sponsor

Aarhus University Hospital

Who can join

18 and older, female only, with Breast Cancer or Breast Carcinoma in Situ. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to contribute to the knowledge regarding immediate implant-based BR by investigating whether the one-stage technique with ADM is superior to the two-stage expander to implant technique. Primary endpoint in first publication is postoperative complications, secondary endpoint is patient and investigator assessed aesthetic outcome. Primary endpoint in second publication is cost, secondary endpoint is patient reported outcome measures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of one-stage direct-to-implant with acellular dermal matrix and two-stage immediate implant-based breast reconstruction-a cohort study.
Brunbjerg ME, Jensen TB, Overgaard J, Christiansen P, et al · · 2021 · cited 8× · PMID 33633977 · DOI 10.21037/gs-20-581

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Aarhus University Hospital trials

Trials by the same sponsor.

NCT07432802 — Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer · NA · not yet recruiting
NCT07499336 — UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST P · not yet recruiting
NCT07454486 — TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cance · not yet recruiting
NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT07426250 — Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04209010 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital
Last refreshed: 3 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04209010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing